Evidence map›Paper›PMID 37504359›Full record

ReviewCurrent oncology (Toronto, Ont.)2023

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials.

Mathilde Weisz Ejlsmark, Tine Schytte, Uffe Bernchou, Rana Bahij, Britta Weber, Michael Bau Mortensen, Per Pfeiffer

Abstract readReview
In one paragraph

Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. New avenues for the treatment of immunotherapy-resistant pancreatic cancer.World journal of gastrointestinal oncology · 2024
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mathilde Weisz EjlsmarkDepartment of Oncology, Odense University Hospital, 5000 Odense, Denmark.ORCID 0000-0002-5161-0891
Tine SchytteDepartment of Oncology, Odense University Hospital, 5000 Odense, Denmark.
Uffe BernchouDepartment of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark.ORCID 0000-0002-5309-2696
Rana BahijDepartment of Oncology, Odense University Hospital, 5000 Odense, Denmark.
Britta WeberDepartment of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Michael Bau MortensenDepartment of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark.ORCID 0000-0002-7270-5005
Per PfeifferDepartment of Oncology, Odense University Hospital, 5000 Odense, Denmark.ORCID 0000-0002-2925-0586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is rising as one of the leading causes of cancer-related death worldwide. Patients often present with advanced disease, limiting curative treatment options and therefore making management of the disease difficult. Systemic chemotherapy has been an established part of the standard treatment in patients with both locally advanced and metastatic pancreatic cancer. In contrast, the use of radiotherapy has no clear defined role in the treatment of these patients. With the evolving imaging and radiation techniques, radiation could become a plausible intervention. In this review, we give an overview over the available data regarding radiotherapy, chemoradiation, and stereotactic body radiation therapy. We performed a systematic search of Embase and the PubMed database, focusing on studies involving locally advanced pancreatic cancer (or non-resectable pancreatic cancer) and radiotherapy without any limitation for the time of publication. We included randomised controlled trials involving patients with locally advanced pancreatic cancer, including radiotherapy, chemoradiation, or stereotactic body radiation therapy. The included articles represented mainly small patient groups and had a high heterogeneity regarding radiation delivery and modality. This review presents conflicting results concerning the addition of radiation and modality in the treatment regimen. Further research is needed to improve outcomes and define the role of radiation therapy in pancreatic cancer.

Indexed as

AdenocarcinomaPancreatic NeoplasmsRadiosurgeryChemoradiotherapyHumansRandomized Controlled Trials as Topicablative radiotherapychemoradiationMR-guided radiation therapypancreatic adenocarcinomaradiotherapystereotactic body radiation therapy

Identifiers

PMID37504359
PMCPMC10378124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.